Cargando…

An Italian Delphi study to evaluate consensus on adjuvant endocrine therapy in premenopausal patients with breast cancer: the ERA project

BACKGROUND: Several trials evaluated the role of ovarian function suppression for the adjuvant treatment of premenopausal patients with hormone receptor-positive early breast cancer. Based on the results of the SOFT and TEXT trials, international guidelines recommend the addition of ovarian function...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pelizzari, Giacomo, Arpino, Grazia, Biganzoli, Laura, Cinieri, Saverio, De Laurentiis, Michelino, Del Mastro, Lucia, Di Leo, Angelo, Gori, Stefania, Guarneri, Valentina, Marchetti, Paolo, Puglisi, Fabio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6161446/ https://www.ncbi.nlm.nih.gov/pubmed/30261866 http://dx.doi.org/10.1186/s12885-018-4843-2

Ejemplares similares

Extended adjuvant endocrine treatment for premenopausal women: A Delphi approach to guide clinical practice
por: Buono, Giuseppe, et al.
Publicado: (2022)

Extended Adjuvant Endocrine Treatment in Luminal Breast Cancers in the Era of Genomic Tests
por: Saponaro, Mariarosaria, et al.
Publicado: (2022)

Controversial topics in metastatic HR+/HER2- breast cancer: Guiding treatment by a modified Delphi approach
por: Fabi, Alessandra, et al.
Publicado: (2022)

Supportive therapies in the prevention of chemotherapy-induced febrile neutropenia and appropriate use of granulocyte colony-stimulating factors: a Delphi consensus statement
por: Adamo, Vincenzo, et al.
Publicado: (2022)

Improved adjuvant endocrine therapy for premenopausal women with endocrine responsive disease
por: Goldhirsch, Aron, et al.
Publicado: (2015)

Adjuvant endocrine therapy for premenopausal women with early breast cancer
por: Bao, Ting, et al.
Publicado: (2007)

Definition of High-Risk Early Hormone-Positive HER2−Negative Breast Cancer: A Consensus Review
por: Garutti, Mattia, et al.
Publicado: (2022)

Emetogenicity of Antibody-Drug Conjugates (ADCs) in Solid Tumors with a Focus on Trastuzumab Deruxtecan: Insights from an Italian Expert Panel
por: Bianchini, Giampaolo, et al.
Publicado: (2022)

CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors
por: Schettini, Francesco, et al.
Publicado: (2018)

Toxicity profile of antibody-drug conjugates in breast cancer: practical considerations
por: D’Arienzo, Andrea, et al.
Publicado: (2023)

Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis
por: Schettini, Francesco, et al.
Publicado: (2021)

T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study
por: Schettini, F., et al.
Publicado: (2021)

Evolving treatments and outcomes in HER2-Positive metastatic breast cancer: Data from the GIM14/BIOMETA study
por: Di Maio, Massimo, et al.
Publicado: (2023)

Prognostic role of amenorrhea induced by adjuvant chemotherapy in premenopausal patients with early breast cancer.
por: Bianco, A. R., et al.
Publicado: (1991)

Health belief about adjuvant endocrine therapy in premenopausal breast cancer survivors: a qualitative study
por: Xu, Lei, et al.
Publicado: (2019)

Adjuvant endocrine therapy for premenopausal women with breast cancer: Patient adherence and physician prescribing practices in Mexico
por: Villarreal-Garza, Cynthia, et al.
Publicado: (2021)

Impact and management of drooling in children with neurological disorders: an Italian Delphi consensus
por: Riva, Antonella, et al.
Publicado: (2022)

Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial
por: Rossi, Lorenzo, et al.
Publicado: (2019)

Controversies in oncology: which adjuvant endocrine therapy is to be given to premenopausal patients with hormone receptor-positive breast cancer?
por: Lambertini, Matteo, et al.
Publicado: (2018)

How to Optimise Extended Adjuvant Treatment with Neratinib for Patients with Early HER2+ Breast Cancer
por: Untch, Michael, et al.
Publicado: (2021)

Metabolic and anthropometric changes in early breast cancer patients receiving adjuvant therapy
por: Arpino, Grazia, et al.
Publicado: (2015)

Unmet Medical Needs in the Management of Ulcerative Colitis: Results of an Italian Delphi Consensus
por: Daperno, Marco, et al.
Publicado: (2019)

Real-World Experience of Methotrexate in the Treatment of Skin Diseases: an Italian Delphi Consensus
por: Damiani, Giovanni, et al.
Publicado: (2023)

Exploring depression in Parkinson’s disease: an Italian Delphi Consensus on phenomenology, diagnosis, and management
por: Stocchi, Fabrizio, et al.
Publicado: (2023)

Exploring depression in Alzheimer’s disease: an Italian Delphi Consensus on phenomenology, diagnosis, and management
por: Padovani, Alessandro, et al.
Publicado: (2023)

Controversies in hormonal adjuvant therapy for premenopausal patients
por: Howell, A
Publicado: (2009)

Prognostic and clinical impact of the endocrine resistance/sensitivity classification according to international consensus guidelines for advanced breast cancer: an individual patient-level analysis from the Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) studies
por: Lambertini, Matteo, et al.
Publicado: (2023)

Biological characterization and selection criteria of adjuvant chemotherapy for early breast cancer: experience from the Italian observational NEMESI study
por: Clavarezza, Matteo, et al.
Publicado: (2012)

Ovarian hyperstimulation in premenopausal women during adjuvant tamoxifen treatment for endocrine-dependent breast cancer: A report of two cases
por: MADEDDU, CLELIA, et al.
Publicado: (2014)

Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT
por: Pagani, Olivia, et al.
Publicado: (2020)

Health-related quality of life in breast cancer patients treated with CDK4/6 inhibitors: a systematic review
por: Di Lauro, V., et al.
Publicado: (2022)

Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer
por: Puglisi, Fabio, et al.
Publicado: (2021)

Combination goserelin and tamoxifen therapy in premenopausal advanced breast cancer: a multicentre study by the ITMO group. Italian Trials in Medical Oncology.
por: Buzzoni, R., et al.
Publicado: (1995)

Adjuvant hormonal therapy in premenopausal women with breast cancer
por: Smyth, Lillian, et al.
Publicado: (2015)

Endocrinology and hormone therapy in breast cancer: Endocrine therapy in premenopausal women
por: Pritchard, Kathleen
Publicado: (2005)

Current State of the Art in the Adjuvant Systemic Treatment of Premenopausal Patients With Early Breast Cancer
por: Parisi, Francesca, et al.
Publicado: (2020)

Results of the ECHO (Eating habits CHanges in Oncologic patients) Survey: An Italian Cross-Sectional Multicentric Study to Explore Dietary Changes and Dietary Supplement Use, in Breast Cancer Survivors
por: Caprara, Greta, et al.
Publicado: (2021)

Luminal-like HER2-negative stage IA breast cancer: a multicenter retrospective study on long-term outcome with propensity score analysis
por: De Angelis, Carmine, et al.
Publicado: (2017)

Corrigendum: Results of the ECHO (Eating habits CHanges in Oncologic patients) Survey: An Italian Cross-Sectional Multicentric Study to Explore Dietary Changes and Dietary Supplement Use, in Breast Cancer Survivors
por: Caprara, Greta, et al.
Publicado: (2022)

Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer
por: Forward, D P, et al.
Publicado: (2004)

Cannot write session to /tmp/vufind_sessions/sess_du1qaech38r3vnnjm09ttaanor